Advances in Clinical Chemistry
- 1st Edition, Volume 103 - June 25, 2021
- Imprint: Academic Press
- Editor: Gregory S. Makowski
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 6 1 6 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 1 0 1 - 5
Advances in Clinical Chemistry, Volume 103, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laborator… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Clinical Chemistry, Volume 103, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laboratory scientists, physicians and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistry. It is the benchmark publication for novel analytical approaches in the clinical laboratory.
- Provides the most up-to-date technologies in clinical chemistry and clinical laboratory science
- Authored by world renowned clinical laboratory scientists, physicians and research scientists
- Presents the international benchmark for novel analytical approaches in the clinical laboratory
Clinical Laboratory Professionals, Physicians and Research Scientists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Autoantibodies to tumor-associated antigens in lung cancer diagnosis
- Abstract
- 1: Introduction
- 2: TAAs and TAAbs
- 3: Common technologies to identify TAAs in LC
- 4: Major issues for identifying TAAs in cancer diagnosis
- 5: Development of TAAbs as biomarkers in LC diagnosis
- 6: Combination of TAAbs with other indicators in LC detection
- 7: The prognostic value of TAAbs in LC
- 8: Conclusion and future perspectives
- Acknowledgment
- Chapter Two: Extracellular vesicles in cardiovascular disease
- Abstract
- 1: Introduction
- 2: Discovery and nomenclature of EVs
- 3: EVs as a potential source for biomarker discovery in cardiovascular disease
- 4: Potential of EVs as therapeutics in cardiovascular disease
- 5: Potential of EVs as drug delivery systems in cardiovascular disease
- 6: Current methods for the isolation of naturally secreted EVs
- 7: Production of EV mimetics
- 8: Summary and perspectives
- Acknowledgments
- Chapter Three: Synuclein in neurodegeneration
- Abstract
- 1: Introduction
- 2: The synuclein family: Structure, functions
- 3: α-Synucleinopathies
- 4: α-Synuclein as a genetic biomarker for synucleinopathies
- 5: Neuroimaging synucleinopathies
- 6: Combination of α-synuclein with other biomarkers
- 7: Conclusions and future considerations
- Chapter Four: Advances in fluorescent probes for detection and imaging of amyloid-β peptides in Alzheimer's disease
- Abstract
- 1: Introduction
- 2: Fluorescent probes of Aβ fibrils/plaques
- 3: Fluorescent probes of soluble Aβ species
- 4: Summary and perspectives
- Chapter Five: Synthetic drugs of abuse
- Abstract
- 1: Introduction
- 2: Synthetic cannabinoids
- 3: Synthetic cathinones
- 4: Laboratory tests
- 5: Treatments
- 6: Summary and future perspectives
- Chapter Six: High-sensitivity methods for cardiac troponins: The mission is not over yet
- Abstract
- 1: Introduction
- 2: Analytical issues
- 3: Clinical issues
- 4: Future trends: As to complete the mission
- Index
- Edition: 1
- Volume: 103
- Published: June 25, 2021
- No. of pages (Hardback): 268
- No. of pages (eBook): 268
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128246160
- eBook ISBN: 9780323851015
GM
Gregory S. Makowski
Dr Gregory S Makowski is a board-certified clinical chemist and fellow of the National Academy of Clinical Biochemistry. Following receipt of his PhD in Biochemistry from the University of Connecticut Storrs, he pursued post-doctoral studies at the University of Connecticut School of Medicine in Farmington that culminated in joint appointments in the School of Medicine and the Department of Laboratory Medicine at John Dempsey Hospital. He has numerous clinical and basic science publications and serves on various scientific and editorial boards. He is actively engaged in the training of Pathology residents and fellows in the Department of Pathology and Laboratory Medicine at Hartford Hospital. He currently serves as Vice President Clinical Laboratory Services Hartford HealthCare in Connecticut.
Affiliations and expertise
Vice President and Chief Scientific Officer, Clinical Laboratory Partners, Newington, CT, USARead Advances in Clinical Chemistry on ScienceDirect